Global Basal Cell Carcinoma Treatment Market Analysis & Forecast 2024-2034, Featuring Cybin, Numinus, Revive Therapeutics, NRx Pharmaceuticals & Mind Medicine

News provided by

Feb 01, 2024, 14:45 ET

DUBLIN, Feb. 1, 2024 /PRNewswire/ -- The "Global Basal Cell Carcinoma Treatment Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.

The recent in-depth analysis of the global basal cell carcinoma treatment market projects a soaring growth trajectory, estimated to burgeon from USD 7.36 billion in 2023 to USD 17.38 billion by the year 2034.

This growth, characterized by a substantial compound annual growth rate (CAGR) of 8.12% during the 2024-2034 period, is largely driven by increasing occurrences of basal cell carcinoma, coupled with innovative advancements in treatment options.

The most common form of non-melanoma skin cancer, basal cell carcinoma, has been the subject of intensive research and development efforts. As a result, new treatment options are emerging, such as AiViva Biopharma's recent promising trial outcomes for AIV001 (Axitinib), an innovative intradermal therapy for patients diagnosed with basal cell carcinoma.

Efforts like these are integral components propelling the market's expansion.
In 2023, the surgery segment is noted to have garnered the highest revenue, thanks to advanced surgical methodologies, and a surge in demand for minimally invasive procedures. Medications are anticipated to exhibit the fastest CAGR in the ensuing years, with tailored medical solutions and increased regulatory approvals such as Libtayo's nod from the European Commission.

The global basal cell carcinoma treatment market's dynamic growth finds a strong base in end-user segments, especially within hospital settings. Hospitals remain essential for patient care, interdisciplinary collaboration, and spearheading treatment innovations. Specialist clinics are also expected to manifest considerable growth rates due to their targeted and specialized treatment approaches.

The regional analysis indicates North America as the leader in revenue generation for the forecast period, driven by high instances of skin cancers, robust research initiatives, and favorable reimbursement landscapes.

However, the Asia Pacific region is not far behind, forecasted to register the fastest CAGR on the heels of an uptick in skin disease cases, treatment awareness, and international collaborations.

Medication
Surgery
Others

End-User Segmentation Emphasizes Critical Role of Hospitals

Specialty Clinics
Hospitals
Others

The comprehensive global basal cell carcinoma treatment market analysis is formulated to aid stakeholders in discerning the nuanced intricacies of market dynamics, high-growth sectors, and the potent strategies adopted by market players that align with current trends and future projections.

Companies Profiled

NeonMind BioSciences
Cybin Corp.
Pfizer Inc.
Usona Institute
Numinus
Jazz Pharmaceuticals
Havn Life
Revive Therapeutics
Seelos Therapeutics
PharmaTher Holdings Ltd
NRx Pharmaceuticals Inc.
Mind Medicine

For more information about this report visit https://www.researchandmarkets.com/r/8i9aoh

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets